Injectable Semaglutide
Semaglutide (the active ingredient in Ozempic® and Wegovy®) works as an agonist on only the GLP-1 (Glucagon-like Peptide-1) receptor, leading to increased insulin release, reduced glucagon secretion, slowed gastric emptying, and increased feelings of fullness, and it is used to improve blood sugar control and, in higher doses, for weight management.
Details
*Activation of the GLP-1 receptor leads to several beneficial effects with both semaglutide
- Increased insulin release
- Reduced glucagon secretion
- Slowed gastric emptying and increased feelings of fullness
- Decreased hunger through satiety pathways
- Up-modulates fat utilization
- Reduced ghrelin levels in the stomach/gut
